HK1223929A1 - -氨基- -二氫- -二氮雜萘 -二酮鈉鹽的晶型 - Google Patents

-氨基- -二氫- -二氮雜萘 -二酮鈉鹽的晶型

Info

Publication number
HK1223929A1
HK1223929A1 HK16112165.6A HK16112165A HK1223929A1 HK 1223929 A1 HK1223929 A1 HK 1223929A1 HK 16112165 A HK16112165 A HK 16112165A HK 1223929 A1 HK1223929 A1 HK 1223929A1
Authority
HK
Hong Kong
Prior art keywords
diazanaphthalene
dihydro
amino
sodium salt
crystalline forms
Prior art date
Application number
HK16112165.6A
Other languages
English (en)
Inventor
Breu Josef
Brysch Wolfgang
Kaiser Astrid
Ludescher Beate
Maass Gerrit
Martin Thomas
Milius Wolfgang
Niedermaier Michael
Original Assignee
Metriopharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43828190&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1223929(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Metriopharm Ag filed Critical Metriopharm Ag
Publication of HK1223929A1 publication Critical patent/HK1223929A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/32Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
HK16112165.6A 2010-03-01 2016-10-24 -氨基- -二氫- -二氮雜萘 -二酮鈉鹽的晶型 HK1223929A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10002067 2010-03-01
EP10075744 2010-11-25

Publications (1)

Publication Number Publication Date
HK1223929A1 true HK1223929A1 (zh) 2017-08-11

Family

ID=43828190

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16112165.6A HK1223929A1 (zh) 2010-03-01 2016-10-24 -氨基- -二氫- -二氮雜萘 -二酮鈉鹽的晶型
HK16112162.9A HK1223836A1 (zh) 2010-03-01 2016-10-24 -氨基- -二氫- -二氮雜萘 -二酮鈉鹽的晶型

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16112162.9A HK1223836A1 (zh) 2010-03-01 2016-10-24 -氨基- -二氫- -二氮雜萘 -二酮鈉鹽的晶型

Country Status (23)

Country Link
US (2) US8772294B2 (zh)
EP (2) EP2774920A1 (zh)
JP (2) JP6061081B2 (zh)
KR (1) KR101770011B1 (zh)
CN (3) CN105859634B (zh)
AU (1) AU2011223226B2 (zh)
BR (1) BR112012021857B1 (zh)
CA (1) CA2791327C (zh)
CH (1) CH704794B1 (zh)
CY (1) CY1115585T1 (zh)
DK (1) DK2542535T3 (zh)
ES (1) ES2487221T3 (zh)
HK (2) HK1223929A1 (zh)
HR (1) HRP20140752T1 (zh)
IL (1) IL221680A (zh)
NZ (1) NZ601689A (zh)
PL (1) PL2542535T3 (zh)
PT (1) PT2542535E (zh)
RS (1) RS53492B1 (zh)
RU (1) RU2585677C2 (zh)
SI (1) SI2542535T1 (zh)
WO (1) WO2011107295A1 (zh)
ZA (1) ZA201206264B (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105859634B (zh) * 2010-03-01 2019-06-28 梅特里奥药品股份公司 5-氨基-2,3-二氢-(2,3-二氮杂萘)-1,4-二酮钠盐的晶型
US10258620B2 (en) 2014-12-18 2019-04-16 Metriopharm Ag Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said form
KR102535960B1 (ko) * 2016-02-16 2023-05-23 메트리오팜 아게 5-아미노-2,3-디하이드로프탈라진-1,4-디온의 새로운 결정질 형태
CN109071461B (zh) * 2016-02-16 2022-06-21 麦翠奥制药公司 制备5-氨基-2,3-二氢酞嗪-1,4-二酮结晶体的方法
EP3248602A1 (en) 2016-05-26 2017-11-29 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae
RU2625267C1 (ru) * 2016-09-22 2017-07-12 Общество с ограниченной ответственностью "АБИДАФАРМА" Способ производства нестерильных субстанций безводного "тамерита" и/или двухводного "галавита" - натриевых солей 5-амино-2,3-дигидрофталазин-1,4-диона (варианты) и способы дальнейшей их переработки в стерильные лекарственные препараты
CA3042956A1 (en) * 2016-11-07 2018-05-11 Metriopharm Ag Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis
CN106810501B (zh) * 2017-01-23 2019-09-10 湖北新德晟材料科技有限公司 一种利用一锅法合成鲁米诺或异鲁米诺的方法
RU2635769C1 (ru) * 2017-02-08 2017-11-15 Адмир Мусаевич Абидов Лекарственный препарат на основе 5-амино-2,3-дигидрофталазин-1,4-диона в виде быстрорастворимой пленки для трансбуккального введения
RU2673452C1 (ru) * 2017-08-15 2018-11-27 Межрегиональное общественное учреждение "Институт инженерной физики" Способ получения активной фармацевтической субстанции, представляющей собой аминодигидрофталазиндион натрия
EP3511325A1 (en) 2018-01-11 2019-07-17 MetrioPharm AG Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione
EP3870175A1 (en) * 2018-10-26 2021-09-01 Immunopharma Plus D.o.o Oral aminodihydrophthalazinedione compositions and their use the treatment of non-viral hepatitis
EP3858328A1 (en) 2020-01-31 2021-08-04 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the inhalatory treatment of inflammatory pulmonary diseases
EP3858358A1 (en) 2020-01-31 2021-08-04 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases
EP4125802A1 (en) 2020-03-25 2023-02-08 MetrioPharm AG 5-amino-2,3-dihydro-1,4-phthalazinedione for treatment of acute lung injury
JP2023529022A (ja) 2020-06-10 2023-07-06 メトリオファーム アーゲー コロナウイルス感染症の治療のための化合物
EP3981405A1 (en) 2020-10-08 2022-04-13 MetrioPharm AG Compound for the treatment of coronaviral infections
AU2021304254A1 (en) 2020-07-09 2023-02-16 Metriopharm Ag Glucocorticoid-sparing agent
CN116963738A (zh) 2020-12-02 2023-10-27 麦翠奥制药公司 用于SARS-CoV-2感染的后遗症的预防和治疗的鲁米诺
RU2756568C1 (ru) * 2021-03-24 2021-10-01 Акционерное общество "Щелково Агрохим" Способ получения натриевой соли 5-амино-2,3-дигидро-1,4-фталазиндиона в гидратированной или безводной форме
EP4193994A1 (en) 2021-12-08 2023-06-14 MetrioPharm AG Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a 6'-methoxycinchonan-9-ol for use in the treatment of coronaviral infections
EP4209219A1 (en) 2022-01-07 2023-07-12 MetrioPharm AG Combination of budesonide and 5-amino-2,3-dihydro-1,4-phtalazinedione
EP4248963A1 (en) 2022-03-25 2023-09-27 MetrioPharm AG Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a fumaric acid ester

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1089086C (zh) * 1988-03-31 2002-08-14 兰德尔·L·米尔斯 鲁米纳得类药物
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
CH683966A5 (it) 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanze attive in agenti anti-ipossici e di difesa.
RU2113222C1 (ru) 1997-09-30 1998-06-20 Закрытое акционерное общество "Центр современной медицины "Медикор" Иммуномодулирующее средство
RU2138264C1 (ru) 1999-05-06 1999-09-27 Абидов Муса Тажудинович Способ получения лекарственного препарата галавит
WO2001072305A1 (fr) * 2000-03-28 2001-10-04 Ramazanov, Ziadin Magomedovich Composition médicamenteuse et procédé de fabrication correspondant
RU2169139C1 (ru) 2000-08-02 2001-06-20 Закрытое акционерное общество "Центр современной медицины "Медикор" Способ получения щелочных и щелочноземельных солей 5-амино-2,3-дигидро-1,4-фталазиндиона
RU2167659C1 (ru) 2000-08-02 2001-05-27 Закрытое акционерное общество "Центр современной медицины "Медикор" Способ коррекции иммунной системы живого организма
RU2211036C2 (ru) 2001-11-20 2003-08-27 Общество с ограниченной ответственностью "Абидофарма" Лекарственный препарат (варианты) и способ его производства
RU2222327C2 (ru) 2002-03-22 2004-01-27 Общество с ограниченной ответственностью "Абидофарма" Способ получения лекарственного препарата
US7326690B2 (en) 2002-10-30 2008-02-05 Bach Pharma, Inc. Modulation of cell fates and activities by phthalazinediones
RU2238730C1 (ru) 2003-02-17 2004-10-27 Абидов Муса Тажудинович Лекарственный препарат
RU2302863C2 (ru) 2003-04-18 2007-07-20 Общество с ограниченной ответственностью "Абидофарма" Лекарственный препарат (варианты)
CN1217193C (zh) * 2003-07-30 2005-08-31 中国药科大学 心肌肌钙蛋白鲁米诺化学发光免疫分析检测方法
AU2003301513A1 (en) 2003-08-04 2005-02-15 Valery Khazhmuratovich Zhilov Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon
PL231885B1 (pl) * 2009-01-16 2019-04-30 Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie
US20100222584A1 (en) 2009-02-06 2010-09-02 Bach Pharma, Inc. Pharmaceutical grade phthalazinediones, process for their preparation and pharmaceutical compositions containing them
CN105859634B (zh) * 2010-03-01 2019-06-28 梅特里奥药品股份公司 5-氨基-2,3-二氢-(2,3-二氮杂萘)-1,4-二酮钠盐的晶型

Also Published As

Publication number Publication date
EP2542535A1 (de) 2013-01-09
DK2542535T3 (da) 2014-07-28
HK1223836A1 (zh) 2017-08-11
WO2011107295A1 (de) 2011-09-09
US9079863B2 (en) 2015-07-14
CN105859634B (zh) 2019-06-28
IL221680A (en) 2015-09-24
CA2791327C (en) 2018-10-30
AU2011223226B2 (en) 2015-04-23
JP2013521239A (ja) 2013-06-10
AU2011223226A1 (en) 2012-10-25
BR112012021857A2 (pt) 2016-05-17
SI2542535T1 (sl) 2014-09-30
IL221680A0 (en) 2012-12-02
HRP20140752T1 (hr) 2014-10-24
ES2487221T3 (es) 2014-08-20
RU2012141274A (ru) 2014-04-20
KR20130019383A (ko) 2013-02-26
CN105859634A (zh) 2016-08-17
JP6206689B2 (ja) 2017-10-04
CY1115585T1 (el) 2017-01-04
US8772294B2 (en) 2014-07-08
EP2542535B1 (de) 2014-05-07
CH704794B1 (de) 2013-04-15
CN105726541A (zh) 2016-07-06
NZ601689A (en) 2014-11-28
JP2016196483A (ja) 2016-11-24
RS53492B1 (en) 2015-02-27
EP2774920A1 (de) 2014-09-10
PT2542535E (pt) 2014-08-25
RU2585677C2 (ru) 2016-06-10
PL2542535T3 (pl) 2014-10-31
CA2791327A1 (en) 2011-09-09
CN102971300A (zh) 2013-03-13
US20140303169A1 (en) 2014-10-09
CN102971300B (zh) 2016-03-02
BR112012021857B1 (pt) 2021-06-22
JP6061081B2 (ja) 2017-01-18
KR101770011B1 (ko) 2017-08-21
US20120329801A1 (en) 2012-12-27
ZA201206264B (en) 2016-07-27

Similar Documents

Publication Publication Date Title
HK1223929A1 (zh) -氨基- -二氫- -二氮雜萘 -二酮鈉鹽的晶型
ZA201206440B (en) [5,6]heterocyclic compound
PL2521450T3 (pl) Grzybobójcze związki heterocykliczne
IL225770A0 (en) Heterocyclic compounds
IL221442A0 (en) Heterocyclic compound
GB0908293D0 (en) Herbicidal compounds
GB0905441D0 (en) Herbicidal compounds
BRPI1015540A2 (pt) ''composto de 1-cianoetil-heterociclilcarboxamida substituídos 750''
ZA201107772B (en) Substituted spiro-amide compounds
EP2519525A4 (en) SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS
ZA201300950B (en) Heterocyclic compound
GB2470828B (en) Fish finder
EP2519522A4 (en) SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS
EP2555766A4 (en) ANTIMETASTATIC COMPOUNDS
EP2616453A4 (en) ANTIMETASTATIC COMPOUNDS
ZA201205726B (en) Substituted naphthalenyl-pyrimidine compounds
GB0917934D0 (en) Herbicidal compounds
IL216338A0 (en) Heterocyclic antiviral compound
IL218500A0 (en) Apogossypolone derivatives as anticaner agents
EP2609093A4 (en) SALT CONNECTION
EP2632255A4 (en) HETEROCYCLIC DIAZENIUM DIOLATE DERIVATIVES
IL217898A0 (en) Crystalline form i rosuvastatin zinc salt
PT2274977E (pt) Anzol
GB0916267D0 (en) Herbicidal compounds
EP2527343A4 (en) HETEROCYCLIC CONNECTION WITH AN AOLA GROUP